An internationally-recognized expert in the mechanisms of neurodegenerative diseases, Dr. Dale Bredesen’s career has been guided by a simple idea: that Alzheimer’s as we know it is not just preventable, but reversible. Dr. Bredesen, who is at the vanguard of neurological research will discuss the science that makes this a reality.

In his paradigm shifting book, The End of Alzheimer’s, Dr. Bredesen offers real hope to anyone looking to prevent and even reverse Alzheimer’s disease and cognitive decline.

Everyone knows someone who’s survived cancer. But no one knows anyone who’s survived Alzheimer’s—until now. Alzheimer’s disease is a global pandemic and the third leading cause of death in the United States. Of the 326 million Americans currently living, approximately 45 million will develop Alzheimer’s disease during their lifetimes unless effective prevention programs are instituted. The 99 percent failure rate of Alzheimer’s drug trials underscores both the area of greatest biomedical failure and the need for a more complete understanding of the drivers (i.e., the root causes) of the disease. Despite these alarming statistics, it has now been demonstrated that early stage Alzheimer’s and its precursors, mild cognitive impairment (MCI) and subjective cognitive impairment (SCI), can be prevented and in some cases reversed.

Join Dale Bredesen as he presents a novel programmatic approach that identifies and targets the multiple contributors to cognitive decline. Based on his findings from over 30 years of research into the mechanisms of neurodegenerative diseases, this approach led to the first published reports of the reversal of cognitive decline. Currently, over 3,000 patients use the protocol described in these initial reports, with success that has not been described previously.

Dr. Bredesen will be joined by Leni Felton, a Board Certified Clinical Nutritionist, specializing in nutrition, natural therapies, and healthy living practices for regaining health. Leni has given three talks at the library int he past regarding reversing cognitive decline using the Bredesen Protocol. She has been in practice since 1995, consulting with individuals at her office in San Ramon and making house calls where she resides in Marin and throughout the Bay Area.

Dale Bredesen, M.D.
Professor, Department of Molecular and Medical Pharmacology
David Geffen School of Medicine at UCLA, Los Angeles, CA
Founding President and CEO, Professor Emeritus, Buck Institute for Research on Aging, Novato, CA

Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner. He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging. In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. He and his group developed a new approach to the treatment of Alzheimer’s disease, and this approach led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014, 2016, and 2018. His book, The End of Alzheimer’s, is a New York Times Bestseller.